No quarterly revenue total was found in Akari Therapeutics Plc's SEC filings.
Akari Therapeutics Plc (AKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-4.81M
-153.7% vs year-ago quarter
Operating cash flow
$-3.11M
+4.5% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
155.76B
+138.8% vs year-ago quarter
Net cash
$2.05M
Q3 FY2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1541157
- Former names
- Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.6M | -$15.8M | -$3.2M | -$7.4M | -$3.1M |
| Net income | -$4.8M | -$14.5M | -$5.3M | -$6.4M | -$1.9M |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$3.1M | -$2.5M | -$3.0M | -$2.1M | -$3.3M |
| Total assets | $38.6M | $33.9M | $47.9M | $45.4M | $50.9M |
| Total liabilities | $20.0M | $19.5M | $19.6M | $22.7M | $25.3M |
| Stockholders' equity | $18.6M | $14.4M | $28.3M | $22.7M | $25.6M |
| Cash and investments | $7.7M | $2.8M | $5.2M | — | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 26, 2026 | Jun 23, 2026 |
All 743 Akari Therapeutics Plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.